Herantis initiated a Phase Ib clinical study in Parkinson's disease with the investigational drug HER-096 in H2 last year. The first results are expected to be completed in the coming weeks, and the full study data will be released by the end of the year.

Read full analysis

Läs mer på Inderes

Ämnen i artikeln

Herantis Pharma

Senast

1,82

1 dag %

6,76%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån